- Home
- ORIC vs ORKA Comparison
ORIC vs ORKA Comparison
Compare ORIC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- ORKA
- Stock Information
- Founded
- ORIC 2014
- ORKA 2004
- Country
- ORIC United States
- ORKA United States
- Employees
- ORIC N/A
- ORKA N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ORIC Health Care
- ORKA Health Care
- Exchange
- ORIC Nasdaq
- ORKA Nasdaq
- Market Cap
- ORIC 362.9M
- ORKA 354.2M
- IPO Year
- ORIC 2020
- ORKA N/A
- Fundamental
- Price
- ORIC $8.17
- ORKA $10.96
- Analyst Decision
- ORIC Strong Buy
- ORKA Strong Buy
- Analyst Count
- ORIC 8
- ORKA 8
- Target Price
- ORIC $18.83
- ORKA $39.71
- AVG Volume (30 Days)
- ORIC 1.6M
- ORKA 143.0K
- Earning Date
- ORIC 05-05-2025
- ORKA 05-14-2025
- Dividend Yield
- ORIC N/A
- ORKA N/A
- EPS Growth
- ORIC N/A
- ORKA N/A
- EPS
- ORIC N/A
- ORKA N/A
- Revenue
- ORIC N/A
- ORKA N/A
- Revenue This Year
- ORIC N/A
- ORKA N/A
- Revenue Next Year
- ORIC N/A
- ORKA N/A
- P/E Ratio
- ORIC N/A
- ORKA N/A
- Revenue Growth
- ORIC N/A
- ORKA N/A
- 52 Week Low
- ORIC $3.90
- ORKA $5.49
- 52 Week High
- ORIC $14.67
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- ORIC 72.38
- ORKA N/A
- Support Level
- ORIC $5.52
- ORKA N/A
- Resistance Level
- ORIC $8.44
- ORKA N/A
- Average True Range (ATR)
- ORIC 0.63
- ORKA 0.00
- MACD
- ORIC 0.32
- ORKA 0.00
- Stochastic Oscillator
- ORIC 93.11
- ORKA 0.00
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.